Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | MDH2 | P40926 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | CTSV | O60911 | 1/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 2/20 | 0.49 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.49 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29951517 | 1.00 | IMPDH2 (0.61) | IMPDH2ALDH1A1HPGDMDH2SMN1; SMN2 | |
| SCHEMBL1791105 | 0.89 | MEN1 (0.60) | IMPDH2ALDH1A1HPGDMDH2SMN1; SMN2 | |
| SCHEMBL9023421 | 0.87 | ALDH1A1 (0.60) | IMPDH2ALDH1A1HPGDMDH2SMN1; SMN2 | |
| SCHEMBL15323162 | 0.85 | ALDH1A1 (0.62) | IMPDH2ALDH1A1HPGDMDH2SMN1; SMN2 | |
| SCHEMBL15323159 | 0.85 | ALDH1A1 (0.62) | IMPDH2ALDH1A1HPGDMDH2SMN1; SMN2 | |
| SCHEMBL9022913 | 0.83 | ALDH1A1 (0.55) | ALDH1A1KDM4EMAPTMAOAMAOB | |
| SCHEMBL29955610 | 0.82 | CYP2A6 (0.51) | IMPDH2ALDH1A1HPGDMDH2SMN1; SMN2 | |
| SCHEMBL2537403 | 0.82 | MAOA (0.57) | IMPDH2ALDH1A1HPGDMDH2SMN1; SMN2 | |
| SCHEMBL2537404 | 0.82 | MAOA (0.57) | IMPDH2ALDH1A1HPGDMDH2SMN1; SMN2 | |
| SCHEMBL27614801 | 0.82 | IMPDH2 (0.58) | IMPDH2ALDH1A1HPGDMDH2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2968272-B1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | ALEVERE MEDICAL CORP (US) | 2021-06-16 | — | — | EP | claimed |
| US-20190290613-A1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | ALEVERE MEDICAL CORPORATION | 2019-09-26 | — | — | US | claimed |
| US-10258605-B2 | Use of indole compounds for fat reduction and skin and soft tissue tightening | ALEVERE MEDICAL CORPORATION (US) | 2019-04-16 | — | — | US | claimed |
| US-20180193309-A1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | ALEVERE MEDICAL CORPORATION | 2018-07-12 | — | — | US | claimed |
| US-20160030389-A1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | ALEVERE MEDICAL CORP (US) | 2016-02-04 | — | — | US | claimed |
| CN-1275942-C | Benzyloxy substituted indole compound and its analog and their production method and application | UNIV FUDAN (CN) | 2006-09-20 | — | — | CN | claimed |
| CN-1569834-A | Benzyloxy substituted indole compound and its analog and their production method and application | UNIV FUDAN (CN) | 2005-01-26 | — | — | CN | claimed |
| EP-3894390-B1 | SYNTHESIS OF (S)-6-HYDROXYTRYPTOPHAN AND DERIVATIVES THEREOF | HEIDELBERG PHARMA RES GMBH (DE) | 2026-05-20 | — | — | EP | disclosed |
| US-12378196-B2 | Synthesis of (S)-6-hydroxytryptophan and derivatives thereof | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-08-05 | — | — | US | disclosed |
| US-20250179018-A1 | SYNTHESIS OF (S)-6-HYDROXYTRYPTOPHAN AND DERIVATIVES THEREOF | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-06-05 | — | — | US | disclosed |
| US-20250177538-A1 | Methods for synthesizing deuterated formylindoles | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2025-06-05 | — | — | US | disclosed |
| CN-113166057-B | Synthesis of (S) -6-hydroxytryptophan and derivatives thereof | 海德堡医药研究有限责任公司 | 2024-12-31 | — | — | CN | disclosed |
| WO-2023250348-A2 | METHODS FOR SYNTHESIZING DEUTERATED FORMYLINDOLES | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2023-12-28 | — | — | WO | disclosed |
| WO-2003016307-A1 | β3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
| WO-2002078693-A2 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
| EP-0548250-B1 | SUBSTITUTED BICYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B4 ANTAGONIST ACTIVITY | RHONE POULENC RORER INT (US) | 1996-03-27 | — | — | EP | disclosed |
| US-5468898-A | Substituted naphthylene compounds exhibiting selective leukotriene B4 antagonist activity | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-11-21 | — | — | US | disclosed |
| EP-0548250-A4 | SUBSTITUTED BICYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4? ANTAGONIST ACTIVITY | — | 1993-10-27 | — | — | EP | disclosed |
| EP-0548250-A1 | SUBSTITUTED BICYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4? ANTAGONIST ACTIVITY. | RHONE POULENC RORER INT (US) | 1993-06-30 | — | — | EP | disclosed |
| WO-1992004321-A1 | SUBSTITUTED BICYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B4 ANTAGONIST ACTIVITY | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250177538-A1 | Methods for synthesizing deuterated formylindoles | TDO2, CISD2, ALAD | IMPDH2 1051/4885ALDH1A1 2258/4885HPGD 105/4885 |
| US-20180193309-A1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | IDO1, FABP4, IDO2 | IMPDH2 371/4885ALDH1A1 1456/4885HPGD 940/4885 |
| US-20190290613-A1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | IDO1, FABP4, IDO2 | IMPDH2 371/4885ALDH1A1 1456/4885HPGD 940/4885 |
| US-20160030389-A1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | IDO1, FABP4, IDO2 | IMPDH2 371/4885ALDH1A1 1456/4885HPGD 940/4885 |
| US-20250179018-A1 | SYNTHESIS OF (S)-6-HYDROXYTRYPTOPHAN AND DERIVATIVES THEREOF | AANAT, HNMT, HTR6 | IMPDH2 1068/4885ALDH1A1 2998/4885HPGD 960/4885 |
| US-12378196-B2 | Synthesis of (S)-6-hydroxytryptophan and derivatives thereof | AANAT, HNMT, HTR6 | IMPDH2 645/4885ALDH1A1 2406/4885HPGD 780/4885 |
| US-10258605-B2 | Use of indole compounds for fat reduction and skin and soft tissue tightening | IDO1, FABP4, IDO2 | IMPDH2 371/4885ALDH1A1 1456/4885HPGD 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.